Faculty of 1000 evaluation for Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

Randomised Controlled ◽

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70026-3 ◽

2013 ◽

Vol 14 (3) ◽

pp. 228-235 ◽

Cited By ~ 112

Author(s):

John FR Robertson ◽

Jean-Marc Ferrero ◽

Hugues Bourgeois ◽

Hagen Kennecke ◽

Richard H de Boer ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomised Controlled ◽

Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

10.1158/1538-7445.sabcs16-p2-08-01 ◽

2017 ◽

Author(s):

I Krop ◽

V Abramson ◽

M Colleoni ◽

FA Holmes ◽

L Estevez ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Phase 2 ◽

Phase 2 Trial ◽

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-11-0070 ◽

2011 ◽

Vol 17 (21) ◽

pp. 6897-6904 ◽

Cited By ~ 63

Author(s):

Erica L. Mayer ◽

Jean-Francois Baurain ◽

Joseph Sparano ◽

Lewis Strauss ◽

Mario Campone ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Trial ◽

Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases

10.1158/1538-7445.sabcs16-ot1-04-05 ◽

2017 ◽

Author(s):

HS Rugo ◽

KC Drumea ◽

M Campone ◽

A Barnadas ◽

O Petrenciuc ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

10.1158/0008-5472.sabcs10-s1-4 ◽

2010 ◽

Cited By ~ 16

Author(s):

PA Kaufman ◽

JM Ferrero ◽

H Bourgeois ◽

H Kennecke ◽

R De Boer ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Locally Advanced ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

10.1158/1538-7445.sabcs17-gs4-07 ◽

2018 ◽

Cited By ~ 6

Author(s):

I Krop ◽

V Abramson ◽

M Colleoni ◽

T Traina ◽

F Holmes ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Phase 2 ◽

Phase 2 Trial ◽

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps621 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS621-TPS621 ◽

Cited By ~ 1

Author(s):

Hope S. Rugo ◽

Rui Li ◽

Oana Petrenciuc ◽

Amily Zhang ◽

Robert E. Coleman

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30786-7 ◽

2020 ◽

Vol 21 (1) ◽

pp. 33-43 ◽

Cited By ~ 16

Author(s):

Aleix Prat ◽

Cristina Saura ◽

Tomás Pascual ◽

Cristina Hernando ◽

Montserrat Muñoz ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Phase 2 ◽

Open Label ◽

Luminal B ◽

Phase 2 Trial ◽

Hormone Receptor Positive

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases

Annals of Oncology ◽

10.1093/annonc/mdw365.89 ◽

2016 ◽

Vol 27 ◽

pp. vi97 ◽

Cited By ~ 1

Author(s):

H. Rugo ◽

O. Petrenciuc ◽

A. Zhang ◽

R. Li ◽

R.E. Coleman

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Abstract PS9-71: The effect of using adjuvant aromatase inhibitors on cognitive functions in postmenopausal women with hormone receptor-positive breast cancer

10.1158/1538-7445.sabcs20-ps9-71 ◽

2021 ◽

Author(s):

Rukiye Guler Ilhan ◽

Yusuf Ilhan ◽

Sema Sezgin Goksu ◽

Ali Murat Tatli ◽

Hasan Senol Coskun

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Aromatase Inhibitors ◽

Cognitive Functions ◽

Hormone Receptor ◽